May 17, 2020

Samsung's Galaxy Note 8.0 Enters The Healthcare Market

3 min
Galaxy Note 8.0
Tablets are becoming increasingly popular in the healthcare industry and systems such as BYOD are fuelling uptake at an astonishing pace. According to...


Tablets are becoming increasingly popular in the healthcare industry and systems such as BYOD are fuelling uptake at an astonishing pace. According to a study carried out by IDG, 41 percent of employees in the US now own a tablet device, so it’s no wonder that a lot of healthcare business is conducted on tablet computers.


At Healthcare Global we have looked at the benefits tablet computers have bought to healthcare, specifically Apple’s iPad and Microsoft’s Surface, and now Samsung’s Galaxy Note is taking its place in the healthcare market with the launch of the Galaxy Note 8.0.

Galaxy Note In Healthcare

The Galaxy Note 8.0 comes with many great features for healthcare professionals; it comes in a number of different sizes to meet the users requirements and is very portable, which is imperative for healthcare professionals and physicians, and it has a number of security features which will appeal to healthcare professionals who may be using the device to access confidential patient information and medical records.

The Galaxy Note provides users with the ability to be more productive and efficient in their work and daily lives. Users will have access to a number of productivity features such as Multi-Window, Polaris Office, Air View, Awesome Note, Group Play and AllShare Play; they will also be able to download healthcare specific applications from the Google app store.

“With the introduction of the Galaxy Note, we defined a completely new category, and one that has been gaining momentum among businesses due to its flexibility in the workplace,” said Tod Pike, Senior Vice President at Samsung’s Enterprise Business Division. “Bringing the Note 8.0 to the Galaxy family of products will bring an additional option for business professionals looking for a device specifically built for the enterprise and flexible enough for a number of industry uses.”

Read Related Articles On Healthcare Global

Unrivaled Safety Features

The Galaxy Note 8.0 incorporates SAFE (Samsung for Enterprise), which offers certified security features, standardized across devices, to ensure reliability. In addition, the Galaxy Note 8.0 features the innovative S Pen to create and edit professional quality work along with note-taking and signature capabilities. Both these features are exceptionally attractive to people working in the healthcare arena as they are dealing with confidential and sensitive information on a daily basis.

The Galaxy Note 8.0 transforms the patient experience by giving physicians a powerful tablet that allows access to patient information wherever it’s needed, integrating with a range of other healthcare solutions. The S Pen also enables physicians to take handwritten notes quickly and easily, saving time and ensuring more accurate input of information.

The Galaxy Note 8.0 went on sale in the US on April 11th 2013 and is set to become a big player in the healthcare tablet market place.

Share article

Jun 16, 2021

NHS opens 8 clinical trial sites to assess cancer treatment

2 min
NHS and OncoHost to launch clinical trials analysing cancer patients response to immunotherapy

The UK's National Health Service (NHS) is opening eight clinical trial sites to assess patients' responses to personalised cancer therapy. 

The trials will analyse how patients diagnosed with advanced melanoma or non-small cell lung cancer respond to immunotherapy, to help predict their response to treatment.  They will be hosted at Gloucestershire Hospitals NHS Foundation Trust facilities. 

Immunotherapy helps the body's own immune system fight cancer, but while it has achieved good results for some cancer patients, it is not successful for everyone. Finding ways to predict which people will respond to the treatment is a major area of research.

OncoHost, an oncology startup,  will provide advanced machine learning technology to develop personalised strategies aiming to improve the success rate of the cancer therapy. The trials will contribute to OncoHost’s ongoing PROPHETIC study, which uses the company’s host response profiling platform, PROphet®

“Immunotherapy has achieved excellent results in certain situations for several cancers, allowing patients to achieve longer control of their cancer with maintained quality of life and longer survival,” said Dr David Farrugia, Consultant Medical Oncologist at NHS, and chief investigator of all eight NHS clinical trial sites.

“However, success with immunotherapy is not guaranteed in every patient, so this PROPHETIC study is seeking to identify changes in proteins circulating in the blood which may help doctors to choose the best treatment for each patient." 

"I am excited that Gloucestershire Oncology Centre and its research department have this opportunity to contribute to this growing field of research and I am determined that our centre will make a leading national contribution in patient recruitment.”

Previous studies in the US and Israel have shown that PROphet® has high accuracy in predicting how patients with cancer will respond to various therapies.

Share article